Paris-based venture capital firm Elaia has finalized its third deeptech seed fund at €134 million, aimed at supporting early-stage European startups in computing, life sciences, robotics, and other deeptech sectors.
- Founded in 2002, Elaia invests in technology and deeptech startups, from seed to growth stages. The firm works closely with B2B founders, providing both funding and operational guidance, and collaborates with research institutions such as PSL Université and Inria to source innovative technologies.
"DTS3 builds on a partnership model we pioneered through the PSL Innovation Fund and Elaia Alpha II Fund, which has already produced notable outcomes including Aqemia, Alice&Bob, and Mablink Bioscience, acquired by Eli Lilly," said Anne-Sophie Carrese, Partner at Elaia.
- Elaia’s investments typically range from €1 million to €13 million across sectors including computing, industrial technologies, life sciences, quantum computing, robotics, and digital health. Through its joint venture Lazard Elaia Capital, the firm can participate in funding rounds at any stage.
- Managing approximately €1 billion in assets, Elaia has completed over 100 investments, supported three companies in reaching unicorn status, and recorded around 80 exits. Its portfolio includes Criteo, Mirakl, Shift Technology, AQEMIA, and Alice & Bob.
- In February, the firm raised €120 million for its fifth Digital Venture Fund to support early-stage European B2B tech companies. It invests €1 to €15 million in areas like AI, cybersecurity, techbio, industrial innovation, and digital infrastructure.
- The fund has completed 11 investments to support pre-seed and seed-stage B2B startups in Europe. It focuses on computing, industrial technologies, life sciences, and emerging areas such as quantum computing, robotics, and digital health.
- Investors in the fund include Bpifrance (through the France 2030 program), BNP Paribas, the Max Planck Foundation, and Lazard Frères Gestion.
